Abzyme Therapeutics is a biopharmaceutical company focused on developing modular single domain VHH antibody fragments for immunotherapy using proprietary antibody generation platforms. The company is located in the Eastern Pennsylvania biotechnology/pharmaceutical hub 30-miles west of Philadelphia.Unique to Abzyme is our proprietary and highly engineered eukaryotic in vitro antibody discovery/optimization platform based on yeast display self-diversifying libraries, rapid target-directed antibody affinity maturation in combination with a FACS single cell sorting approach to identify desired antibodies. Abzyme's modular antibody discovery platform incorporates a real-time screening ability to select for key properties such as epitopic diversity, binding affinity, expressibility, solubility, developability, broad-reactivity and target-specificity.Today, the Company has over 60 proprietary and partnered programs in development in therapeutic and diagnostic areas including infectious diseases, immuno-oncology, ophthalmology, inflammation and central nervous system disorders.

Antibody devlopment Antibody optimization Antibody engineering Antibody production Therapeutic antibody Bispecific Antibody T-cell engaging antibody Camelid VHH antibody Human recombinant antibody Single domain antibody Immunotherapy Human VH Rabbit Mab CNS Modular Antibody Central nervous system Blood-brain barrier pre-targeted immunotherapy anti-digoxigenin antibody DIG-directed bispecific antibodies Opnthalmology